A group of Massachusetts-based researchers say they believe omicron could already account for about 15% of COVID-19 cases in some parts of the U.S.
Author: Elizabeth Weise and Karen Weintraub, USA TODAY
An early glimpse of omicron’s threat: High transmission likely, but vaccines provide hope
Many experts believe vaccines will likely continue protecting against severe disease, but the mutated variant may prove highly infectious.
FDA panel supports J&J COVID-19 vaccine booster shot for all Americans who got a first dose
In an unanimous vote, a federal advisory committee supported boosters of the J&J vaccine for all adults at least two months after a single shot.
Who should get COVID-19 boosters first? CDC committee set to vote Thursday – but only on Pfizer vaccine
Among the more than 20,000 people who have been tracked after receiving a third dose, no major safety concerns have popped up, CDC officials say.
Pause on Johnson & Johnson COVID vaccine in US lifted by FDA, use to resume
The pause on the one-dose J&J COVID vaccine will be lifted and distribution will resume in the U.S., FDA officials said Friday night.
Vaccine passports should be free, private and secure, White House says. But who will be issuing them?
Israel has a “green card” to prove that people have been vaccinated and other countries are contemplating requiring proof of vaccination for entry.
Amid a chaotic COVID-19 vaccine rollout, states find ways to connect shots with arms
Under a decentralized national health care system and a chaotic COVID-19 vaccine rollout, states find their own ways to reach and vaccinate residents.
The COVID-19 vaccine life cycle: from DNA to doses
Making a vaccine against the coronavirus is a complicated, months-long process. Pfizer’s is working to get it done faster. It still takes time.
Where did COVID-19 come from?
As the U.S. marks one year since its first case, questions remain about the origin of the coronavirus that causes the disease. The answers matter.
CDC-convened committee votes to add nursing home residents to first phase of COVID-19 vaccine access
Everyone in Phase 1a should be able to get the first of the two-shot COVID-19 vaccine series within three weeks of one being authorized by the FDA.